From: Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
Analysis / adapted parameters | Comments | ICER [EUR/LYG] FIT vs. Colonoscopy | |
---|---|---|---|
Base case | 14,960 | ||
Survival probability | Survival probability for patients diagnosed with cancer unadjusted for mode of detection | 17,595 | |
Participation rate | Colonoscopy 20.0%; FIT 38.9%, gFOBT 31.1% | FIT is dominant | |
Participation rate | Colonoscopy 28.0%; FIT 38.9%, gFOBT 31.1% | FIT is dominant | |
Costs examination | Cost for screening colonoscopy examination EUR 352, polypectomy EUR 98 | 15,853 | |
Test accuracy | Relative reduction of sensitivity of FIT and gFOBT (0%; 60%)a | 14,960 | 58,131 |
Discount rate | Assumed discount rate (0; 10%) | 8493 | 48,911 |
Costs examination | Relative increase in costs of colonoscopy examination and polypectomy (0, 100%) | 14,960 | 16,156 |
Costs treatment | Inpatient-care costs treating cancer stage UICC IV (relative increase 0, 50%) | 14,960 | 14,678 |